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The electrophysiologic effects of the antiarrhythmic drugs, presented elsewhere in this symposium, form only one of the bases for the selection of a therapeutic agent in any given clinical
situation. The final choice depends at least on the
following factors:
1. The specific arrhythmia
2. Underlying heart disease, if any
3. The degree of compromise of the circulation, if any
4. The etiology of the arrhythmia
5. The efficacy of the drug for that arrhythmia
due to that etiology
6. The toxicity of the drug, especially in the
given patient with possible alterations in
volume of distribution, biotransformation,
and excretion
7. The electrophysiologic effects of the drug
8. The routes and frequency of administration
available for that drug
As no one drug meets, or even approaches,
the criteria for the ideal antiarrhythmic, a knowledge of several drugs is essential. Unfortunately,
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adequate, controlled clinical comparisons are virtually nonexistent.
A complete presentation of the non-electrophysiologic pharmacology would include the following considerations:
1.
2.
3.
4.
5.
6.
7.
8.

Absorption and peak effect times
Biotransformation
Rate of elimination or half-life (t1d
Drug interactions
Toxicity
Clinical usefulness
Therapeutic drug levels
Dosage schedules

As all of the above data cannot be presented in
the limited space available, only selected items will
be discussed. Much of the preceding information
is available, however, in standard texts ( 17, 10).
(See Addendum 1)
Quinidine. Quinidine is principally transformed in the liver by hydroxylation, but some 1050% is excreted unchanged in the urine. This variation in the quantity excreted in the urine is of
considerable importance, and it is influenced by
both glomerular filtration and by urine pH.
Bellet et al. ( 3) measured the serum levels
of quinidine in three groups of ten subjects after
600 mg of oral quinidine. Normal subjects had, af53
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ter two hours, significantly lower serum quinidine
levels than the subjects with congestive heart failure
( creatinine clearances of 35-80 ml per minute), or
the subjects with renal disease and azotemia. While
this study does not consider alterations in the volume
of distribution, liver function, and so forth, the correlation between the peak level of quinidine and
the rate of fall of the serum levels with glomerular
filtration is evident. Thus, we must consider renal
function much in the same way as when we use
digoxin.
In addition to renal function, the pH of the
urine is important in the excretion of quinidine. As
urine pH rises, more of the urinary tubular quinidine
is nonionized and, hence, more readily passes across
the tubular epithelium, thus decreasing the quantity
of filtered quinidine excreted in the urine.
Figure 1 is taken from the study of Gerhardt et al.
(9). In normal subjects, urine pH was raised
by administering acetazolamide and sodium bicarbonate. As shown, serum quinidine levels rise as urine pH increases and, furthermore, the pharmacologic significance of the higher serum quinidine
levels is indicated by progressive increase in the QT interval.
Molar sodium lactate has been recommended as

a means of treating the arrhythmic abnormalities associated with quinidine toxicity. While such alkalizing therapy may improve the arrhythmias, it surely
will also delay the excretion of quinidine and
might prolong the duration of the toxicity. Also a
large segment of the population has been consuming a very effective urinary acidifier, ascorbic acid, in
a huge dose. The doses of quinidine needed to establish an antiarrhythmic effect might be titrated
in such an individual, who then discontinues the
ascorbic acid . A considerable increase in serum
quinidine could occur with a significant chance of
serious toxicity.
Thus the physician must consider glomerular
filtration rate and urine pH when prescribing quinidine. Alterations in liver function and the apparent
volume of distribution are probably also important
but less quantifiable.
The serum half-life (t 112 ) is known for all of
the available antiarrhythmic drugs, and this simplified concept is useful in understanding the necessity
for loading doses, the frequency of dosing, the duration of toxicity, and the timing of clinical observations of the patient.
The serum half-life is defined as the time required to reduce the serum level of a drug to one-
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Fig. I- Change of serum quinidine and change of ratio of measured Q-T interval to the maximum normal Q-T interval at measured
heart rate (expression of quinidine effect), plotted relative to urine pH, for two subjects. (Reproduced by permission of Annals of
Internal Medicine, 71 :929, 1969, and R. E. Gerhardt).
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half its initial level. As the great majority of drugs
follow first-order kinetics (the amount eliminated
is proportional to the quantity present), the following "rules" of half-life are widely applicable:
1. The serum half-life is independent of the

quantity of drug present. In figure 2, the
disappearance curve declines 50% each
half-life, decreasing from 100% to 50%
the first half-life, from 50% to 25% the
second half-life, and so forth.
2. The half-life concept is independent of the
mechanism of elimination ; urinary or intestinal excretion, hepatic transformation, and
so forth .
3. The dosing interval must be shorter than
the half-life to avoid wide fluctuations in
serum levels and body stores of a drug.
4. Essentially complete elimination of a drug
is achieved after five half-lives and conversely, with regular dosing, at frequencies
of the half-life, or more often, equilibrium
levels are achieved after five half-lives (see
accumulation curve) . After 3.3 half-lives,
90 % of equilibrium levels are achieved. This
would then be an appropriate time to make
clinical observations on the pharmacologic
effects of the drug.
For quinidine, the half-life is about 4-6 hours.
Doctors Richardson, Zee, and Wyso (21) from our
institution reported on studies in which quinidine
was given at 9 A.M., 1, 5, and 9 P .M. While the serum
levels before the next day's dose were still adequate,
they were achieved at the expense of excessive
levels one and one-half hours after the 9 P.M. dose.
A six-hour schedule would have avoided the potentially toxic levels at bedtime.
In a study to be described further . below,
Bloomfield et al. (7) gave patients quinidine 300
mg at 0, 3, and 6 hours, as a loading attempt and
then gave 300 mg every 6 hours thereafter. Fig-
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ure 3 shows that the serum concentrations did not
reach equilibrium levels until after 24 hours, in
keeping with the principles noted above.
In summary, application of the rules of t 112
to quinidine suggests that where prompt action is
needed, a loading dose should be given and that
quinidine should be given every six hours to avoid
peaks and troughs of serum levels and associated
toxicity and subtherapeutic concentrations.
"Quinidine Syncope" is the name employed
by Selzer and Wray (23) to describe recurrent
ventricular fibrillation, usually self-terminating, seen
in patients treated with quinidine. It usually occurs
after the first few doses, and it may be noted in
patients with normal or even low serum quinidine
levels. While tachyarrhythmias and ventricular fibrillation are well-known toxic effects of quinidine, these
individuals seem to be unusually susceptible to this
serious adverse effect. While most patients receiving
quinidine have underlying heart disease, quinidine
syncope can occur in patients with no detectable
organic heart disorder.
Some clinicians are attempting close monitoring
of patients during the initiation of quinidine therapy.
The effectiveness of such monitoring will be difficult to assess because of the infrequency of this syndrome. Selzer and Wray estimated that 3-5% of
patients treated with quinidine may develop this
idiosyncratic toxicity, but Bjerkelund (6) reported
only l + % and Lown ( 16) reported only 0.5%
sudden deaths in his series of 650 patients.
Finally, in regard to quinidine, some note of
its efficacy need be made. Bloomfield et al. (7) studied 53 patients with acute myocardial infarction in a
placebo controlled, randomly allocated prospective
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Fig. 2-The accumulation and disappearance of a drug is
depicted in terms of its half-life.

Fig. 3-Blood quinidine concentrations at various intervals
during five days of prophylactic quinidine thera,py in 27
patients with acute myocardial infarction. (Reproduced by
permission of the New England Journal of Medicine, 285 :
981, 1971, and S.S. Bloomfield) .
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trial of oral quinidine ( vide supra). Because of the
lag in achieving therapeutic serum quinidine levels,
there was no difference between the treated and
placebo groups in the first six hours, but thereafter
(see fig. 4), there was a statistically significant reduction in premature ventricular and supraventricular contractions and in "serious ventricular arrhythmias." As has also been true of the studies of other
antiarrhythmics in acute myocardial infarction, there
was no difference in mortality between the treated
and control groups.
Beta Adrenergic Receptor Blockers. The serum half-life of oral propranolol (Inderal®) is 3-4
hours. Successful management with less frequent
dosing intervals is likely due to the fact that the
large doses used result in blood levels which remain
above the therapeutic level for a longer period of
time.
The major concern in beta-blocker therapy is
the marked cardiovascular depression which these
agents induce. In three separate series of dogs, we
(19) determined the mean doses of three antiarrhythmic drugs required to convert ouabain (a cardiac glycoside)-induced ventricular tachycardia to
normal sinus rhythm. Alprenolol is an effective
beta-blocker, the dose of which (intravenously)
does not differ from propranolol. These doses of the
three antiarrhythmics were then studied in a new

series of paced, open chest dogs, and the electrocardiographic and hemodynamic effects of these drugs
given in "equi-antiarrhythmic" doses are depicted
in figure 5. The beta-blocker significantly prolonged the P-R and Q-T intervals and depressed
blood pressure, cardiac output (aortic flow via an
electromagnetic flow transducer), and left ventricular contractility ( dp/ dt, peak left ventricular
rate of pressure rise). Directionally similar but less
marked alterations occurred with procainarnide, while
diphenylhydantoin did not affect these or any of
the other measured cardiovascular functions. Betablockers are, therefore, the most likely of the antiarrhythmics to induce cardiac depression, and even in
low doses, a worsening of heart failure or the precipitation of pulmonary edema may result. While it
is true that the correction of an arrhythmia by the
beta-blocker may so improve the heart's overall
function as to counteract any direct myocardial depression, such therapy is fraught with the danger that
should the beta-blocker not affect the arrhythmia,
its negative inotropic action will still be manifest.
Except where an arrhythmia is caused by
adrenergic mechanisms, beta-blockers are best
avoided in patients with myocardial disease unless
other therapy has failed and the situation is desperate.
Diphenylhydantoin. Diphenylhydantoin (DPH) is
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Fig. 5-The responses to equi-antiarrhythmic doses of
alprenolol, diphenylhydantoin, and procainamide are shown.
Statistically significant (P < .05) changes from control are
indicated. (Reproduced by permission of Archives Internationales de Pharmacodynamie et de Th erapie, 190:354,
1971, and J. D . Proctor).
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of particular interest. The differences in its electtophysiologic effects have already been noted elsewhere. Also, any consideration of DPH must include
information about its pharmacokinetics and biotransformation.
Diphenylhydantoin is slowly absorbed by
mouth , peak levels not being achieved for hours.
This drug should not be given intramuscularly sirice
its absorption is erratic. Even intravenously, DPH
effect requires 1-5 minutes , and rapid (bolus) injections must be avoided.
The biotransformation of DPH is shown in figure 6. Diphenylhydantoin is parahydroxylated by
oxidizing enzymes in the liver microsomes, converting DPH to HPPH (hydroxyphenyl, phenylhydantoin or 5 phenyl 5'parahydroxyphenylhydantoin).
It is this enzyme which is so susceptible to both enzyme inhibition and enzyme induction, accounting
for the large number of reported DPH drug interactions (see addendum 2). Hydroxyphenyl, phenylhydantoin, the inactive metabolite, is conjugated with
glucuronide, and its excretion in the urine normally
accounts for about 75% of the elimination of
DPH. Letteri et al. (15) have found that patients
with uremia have lower seru m levels of DPH than
do normal subjects receiving the same dose, and
that furthermore, the t 11 2 in uremia is shorter (more
rapid DPH disappearance). This, of course, is quite
the opposite from most drugs where renal failure
results in higher serum levels and longer t11 2 . The
mechanism whereby lower DPH levels are seen in
uremia has not been completely elucidated, but
several possible mechanisms have been suggested.
It is known that HPPH levels are higher in uremic
patients. It might be that something in the uremic
state induces the parahydroxylating enzyme, hence
more rapidly converting DPH to HPPH, or it may be
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Fig. 6-Major route of metabolism of DPH. (Reproduced
by permission of the New England Journal of Medicine,
285: 651, and Joseph M. Letteri).
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that the renal failure blocks the excretion of HPPH
which competes with DPH for serum protein binding
sites (see fig. 6). The unbound, free DPH would
be more accessible to enzymatic conversion to
HPPH and also more accessible to its receptor site.
Thus, while total DPH would be reduced, the free
(active) portion might be normal. Finally, it is
known that serum protein binding is altered in uremia and this, too, could account for the lower total
DPH and its more rapid conversion to HPPH due to
more of the serum DPH existing in the free, unbound form.
The clinical role of DPH is receiving more
attention. Lown and Wolf (16) report studies in
which ventricular fibrillation was induced in dogs
by occluding, and if necessary, later releasing the
occlusion, of the anterior descending coronary artery. About 75 % of untreated dogs developed ventricular fibrillation, and pretreatment with DPH
had no effect. On the other hand , pretreatment with
procainamide reduced the incidence of ventricular
fibrillation to about 20 %; quinidine, lidocaine,
practolol (a beta-blocker), and bretylium tosylate
reduced it to about 3 5 % ; and dextro-propranolol and
ajmaline reduced ventricular fibrillation to about
50 %.
Last year an Australian cooperative group reported a clinical trial of DPH prophylaxis in patients
discharged from the hospital after their first acute
myocardial infarction (8). Diphenylhydantoin, 300400 mg per day, was given to 283 patients while the
control group received 3-4 mg per day. Although
the high dose DPH group had less palpitations and
less documented arrhythmias than the control group,
survival was unaffected.
Mercer and Osborne (18) in 1967, noted that
the etiology of the arrhythmia was a significant factor in predicting its response to DPH. Where the
arrhythmia was due to digitalis intoxication, onehalf of the patients were successfully managed with
DPH, but where the arrhythmia was due to coronary heart disease, only about one-fourth responded. (These percentages may not represent
the maximum efficacy of DPH as the dosage schedules suggested below were not employed.)
From these data, it would appear that digitalis
intoxication is the prime indication for DPH and
that its usefulness in coronary heart disease is likely
to be limited.
The effective serum concentration of DPH was
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established by the elegant studies of Bigger and
his colleagues (5) (fig. 7) . These data indicate an
effective level of about 6-18 µg per ml, the same
range as that established for anti-convulsant efficacy
(10-20 µg per ml).
Diphenylhydantoin does not follow first-order
kinetics as even usual doses approach saturation of
the parahydroxylating enzyme system. Thus, the
"rules" of half-life do not, strictly speaking, apply
to DPH. In the effective serum level range, however, DPH serum levels decline by one-half over
18-24 hours. It is evident then, that without a loading dose, several days will be needed to achieve
equilibrium levels. Kutt and McDowell ( 14) and
Bigger et al. ( 5) have recommended the following
dose schedule for prompt DPH effect:
Day
1
2
3
Thereafter

Dose (mg)
1,000
500-600
500-600
400-500

Where urgent indications exist, DPH may be
given intravenously, 50-100 mg at 5 minute intervals
until a therapeutic effect, a toxic effect, or 1,000 mg
is given ( 5) . If less than 1,000 mg is given IV, the

NUMBER OF
PAT I ENTS

PLASMA OPH LEVEL ()Jg/m il

Fig. 7-Plasma levels at which ventricular arrhythmias
were abolished. Plasma DPH concentrations are plotted
on the abscissa. The number of patients whose arrhythmia
was abolished in each range of plasma level is represented
on the ordinate as unfilled bars. The one patient whose
arrhythmia was unaffected by DPH is represented by the
filled bar; this unresponsive arrhythmia was a typical ventricular parasystole. Seventy percent of the conversions occurred at plasma concentrations between 1O and 18
µg / ml. Only one patient required a plasma concentration
above 18 µg / ml before conversion occurred. (Reproduced
by permission of the American Heart Association from
Circulation , 38:367, 1968, and J . T. Bigger, Jr.).

rest of the loading dose may be given slowly IV
or orally over the next 6-18 hours. Where less
urgency exists, the 1,000 mg should be given orally
over 6-18 hours .
One last point needs to be made in regard to
DPH. This is one of the very few currently available drugs for which generic non-equivalence exists.
(Digoxin is the other important example.) Generic
brands of DPH have been shown to result in higher
serum levels than the first marketed product, Dilantin®. An "epidemic" of DPH toxicity occurred
when the source of supply of DPH was changed to
a generic product and its greater bioavailability resulted in toxic effects in previously stable patients
with convulsive disorders (25). Patients on DPH
should receive a single manufacturer's product.
Bretylium Tosylate. Bretylium tosylate, BT, is
a drug of considerable current interest. It is available only on an investigational basis, viz., it is not
approved for marketing in this country.
Much of the action of bretylium can be understood in light of its effects on the sympathetic neuron. Norepinephrine is present in the terminal sympathetic neurons in two pools, a larger storage pool
and a smaller labile pool. Bretylium tosylate does
not affect the former, but its acute administration
causes a sudden release of norepinephrine from
the latter. This release of norepinephrine accounts
for a number of the early effects of parenterally
administered BT, such as the early transient hypertension, enhanced automaticity, and increased conduction velocity. The initial positive inotropic effect
( increased myocardial contractility) is largely, if not
totally due to this norepinephrine release. Chronic
bretylium therapy does, however, cause a supersensitivity to circulating and infused epinephrine
and norepinephrine since BT blocks the sympathetic neuronal uptake of these catecholamines,
the major route of modulating the catecholaminereceptor action. This same uptake mechanism also
accounts for a number of bretylium drug interactions as BT competes with tyramine, amphetamines,
and metaraminol (Aramine®) for uptake. The tricyclic anti-depressants also block BT uptake and
antagonize its effect, as they do, too, for guanethidine (lsmelin@).
Bretylium is excreted unchanged in the urine.
Its serum half-life is unclear. Kuntzman et al. (13)
studied four normal subjects and found a nonexponential decline of serum levels with the rate of
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disappearance quite rapid early (t112 = ± 1 hour)
and somewhat slower later (t 112 = ± 5 hours). Romhilt and associates (22), using the serum method
established by Kuntzman, studied eight patients.
They found an exponential decline of serum levels
with a tu2 = 10 hours (fig. 8). There was no apparent
relationship between the t 11 2 and the levels of
BUN in this latter study, and personal communication failed to resolve this discrepancy. The t 11 2
value for bretylium tosylate may not be critical,
however, since, as shown in figure 8, there is a
temporal disparity between the serum levels and
the antiarrhythmic efficacy. Bretylium tosylate
may, therefore, be one of the so-called "hit-and-run"
drugs (12). On the other hand, there appears to be
an excellent correlation between the hypotensive
effects and the serum levels of this "peripheral
sympathetic blocker." This temporal dispersion of
hypotensive and antiarrhythmic action prompted
these authors (22) to suggest that BT's antiarrhythmic effect may not be related to its action on the
sympathetic neuron.
There are both animal and human data to suggest that other antiarrhythmic drugs antagonize the
effects of bretylium. Bernstein and Koch-Weser (4)
found that patients concurrently receiving other
antiarrhythmic drugs were less likely to respond to
BT, confirming the observations of Bacaner (2) in
experimental animals. Therefore, it would appear
wise to discontinue all other antiarrhythmics when
initiating bretylium therapy.
Bernstein and Koch-Weser (4) noted the following incidence of adverse effects:
Side Effects of Short-Term Bretylium Therapy in
30 Patients

%
Hypotension
Hypertension
Initial increase in arrhythmias
Nausea or vomiting
Involuntary head movements
Headache

63
17
13
10
3
3

In only one of the 19 patients with hypotension
did the decline in blood pressure exceed 20 mm Hg.
As these patients were recumbent and as the hypotensive effect of BT is largely orthostatic, such results could be anticipated ( vide infra). Transient
hypertension and transient enhanced automaticity
(increase in arrhythmias) were surely related to
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the initial release of norepinephrine. Nausea and
vomiting are rare with intramuscular administration, but common if bretylium is given intravenously.
Chronic oral administration commonly produces
severe, persistent parotid pain during mastication.
This pain is of sufficient magnitude to be the major
cause for discontinuing chronic oral therapy. Postural hypotension is a problem early, but tolerance to
this action develops fairly promptly.
The clinical role of bretylium is still unclear, but
the drug may find a place in the management of
recurrent severe ventricular tachyarrhythmias, viz.,
ventricular tachycardia, and ventricular fibrillation.
Bacaner reviewed 250 reported cases of ventricular tachyarrhythmias ( 1). Eighty-five percent re-
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continued until the ninth hour after administration. By
contrast 50% suppression of mean PVC frequency began
at the sixth hour and continued until the 18th hour. The
mean elimination half-life of bretylium was about 10
hours. N refers to number of patients. (Reproduced by
permission of the American Heart Association from Circulation, 45 :804, 1972, and D . W. Romhilt ) .
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sponded favorably. Romhilt et al. (22) continuously
monitored eight patients with frequent premature
ventricular contractions (fig. 9) . The effectiveness
of bretylium tosylate, 4 mg per kg intramuscularly, is
evident after a six-hour lag. Bernstein and KochWeser (4) found an excellent response in 18 of
30 patients with ventricular tachycardia unresponsive to other drugs. Five patients had a partial response and in seven, no response was evident.
Those failing to respond were more often receiving
other antiarrhythmic drugs concurrently and were
more likely to have had the arrhythmia for a longer
period of time. These authors rightly caution against
an over zealous interpretation of these data, noting
that had these patients been first treated with bretylium, the failures could well have responded to
whatever the second drug might have been.
One negative report is noteworthy. Taylor
et al. (24) studied 101 patients during acute myocardial infarction. Sixty-three patients received
bretylium, 300 mg IM every 6 hours. In 25 of
the 63, therapy was discontinued because of adverse effects, four due to nausea and vomiting and
21 due to hypotension. In these 21 patients, blood
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Fig. 9-Mean PVC frequency during treatment days compared with control days. There was 50 % supression of
mean PVC frequency in the second and third 6-hour intervals following bretylium 4 mg/ kg (solid bars) , while no
suppression was seen after 2 mg/ kg ( shaded bars). Control
days are shown in stippled bars. N refers to number of
patients. On day 1, data were not obtained in one patient
during the first 12 hours due to recording-equipment failure.
(Reproduced by permission of the American Heart Association from Circulation, 45: 805 , 1972, and D. W . Romhilt).

pressure averaged 65/ 40 mm Hg, a marked degree
of hypotension for patients with acute infarction. It
is likely that the unstable state of the circulation in
such patients and their use of bedside commodes,
thus enhancing orthostasis, accounts for the strikingly
higher incidence of significant degrees of hypotension than those noted in the table above. Furthermore,
among those who continued BT therapy, there was
no decrease in ventricular arrhythmias. Supraventricular arrhythmias, however, were less in the
treated group. Again, one patient died in each of the
treated and control groups.
Finally, the role of bretylium tosylate in the
management of digitalis-induced ventricular tachyarrhythmias should be considered. Our group (20)
infused ouabain in a group of ten dogs. In half, the
ouabain was continued until stable ventricular tachycardia was established. Bretylium was then given in
incremental doses, beginning with 5 mg per kg and
increasing to 40 mg per kg total dose. In every dog,
the ventricular tachycardia not only persisted, but
indeed, the ventricular rate accelerated. Furthermore, when the ouabain infusion was stopped at
the time frequent ventricular premature contractions had occurred, bretylium, in each of the five
dogs, promptly induced ventricular tachycardia (fig.
10). This augmentation of automaticity by BT was
also noted by Kleiger and Shander (11). They produced ventricular tachycardia in dogs with acetylstrophanthidin (another cardiac glycoside). When
the tachycardia had subsided spontaneously after
cessation of the glycoside, they administered bretylium and a recurrence of the ventricular tachycardia
ensued. Both of these animal studies were completed before the time of maximal antiarrhythm ic
efficacy of BT, but they indicate the potential danger during the period of initiation of such therapy.
In conclusion, time and space have not allowed a classical pharmacological discussion of these
four important antiarrhythmic drugs. In order to
use a drug rationally so as to obtain a maximum
efficacy: toxicity ratio, one must understand the
drug's absorption, its route and mechanism of biotransformation, and its effective half-life. Such data
are available for the antiarrhythmic drugs.
Where the achievement of one's therapeutic
goal is so readily measurable, as it is with antiarrhythmic drugs, we must demand of ourselves a
more knowledgeable and rational therapeutic approach.
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PANEL DISCUSSION

Dr. Surawicz: I use quinidine less, and some people
have stopped using it. This is actually the only true
antiarrhythmic drug because it is the only drug that
will reasonably consistently convert atrial fibrillation to sinus rhythm. As Dr. Hoffman pointed out, its

effect on conduction would have predictable effects
on the electrocardiogram in terms of prolongation
of the QRS complex and the P-R interval, and
with increasing concentration of the drug, which is
increasing the dose, we have evidence of increasing

Addendum l
ANTIARRHYTHMIC DRUGS
EFFECT OF DRUG ON HEART
Refractory
Period

Inotropic
State

Quinidine

l

i

l

Procainamide
(Pronestyl ®l

l

i

l

0

l

0

0

2-5

l

l

l

H

Beta-adrenergic
Blocking

.05-.15

0

0

6-18

Lidocaine
(Xylocaine ®l

0

Propranolol
(lnderal ®)
Diphenylhydantoin
(Dilan tin ®)

Bretylium
(Daren thin®>

i

Initialj

Initialj
thenl(?)

Initialj
then O

Initiall
thenj

Initialj

Autonomic
Effects

Therapeutic
Plasma Levels
µg / ml

Conduction
Velocity

Name of Drug

Automaticity
Atrium
Ventricle

Vagolytic

3-6

Vagolytic

4-8

NE Release
Followed by
Sympath Block
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prolongation of P-R and ORS intervals. This is a
dose related toxicity that we can avoid by keeping
our doses down. Dr. Wasserman discussed the quinidine induced ventricular fibrillation and pointed out
that this is not necessarily a dose related effect.
This occurs when the concentrations are therapeutic
and the ORS interval is not widened and the P-R
is not prolonged. Therefore, we have no warning,
and that is much more frightening because this
cannot be avoided. Now, does th at mean that we
should stop using quinidine? I, of course, asked
that question and observed some quinidine syncope,
the same kind of record as was shown from Dr.
Selzer's and Dr. Wray's paper. Then I reviewed all
available data on quinidine toxicity and came to
the conclusion that all published reports that I
have been able to review showed three things:
first, all people had severe heart disease; second,
all people were treated with digitalis; and third, in
spite of quinidine syncope not being dose related,
they all received more than 1.2 g of quinidine per
day. I concluded that I have not had any evidence
that lower doses will induce fibrillation. On that
basis I still use quinidine, and I wonder whether you
would like to comment on that.
Dr. Wasserman: Yes. In some of the cases it is clear
that preceding the fibrillation there was prolongation
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of the 0-T interval ; thus, whether or not this is
predictable in the majority of cases, I do not know .
It certainly would be in some, and it is for this
reason that we are monitoring. I can tell you about
a case in which a young lady who had no heart
disease whatsoever was erroneously treated for
VPC's which I am sure in retrospect were due to
alcoholism. In the absence of digitalis and with
standard doses she developed this syndrome. She
was shocked 20 or 30 times with typical findings .
We did not have a quinidine level in her, but her
renal function was normal , her heart was normal,
and we simply stopped the drug. Within the usual
six hour period, actually four hours, she stopped
having ectopic activity and stopped her recurrent
bouts of ventricular fibrillation. Subsequently, we
have found normal and even low levels of serum
quinidine in patients exhibiting quinidine syncope,
including cases where syncope followed a single
usual initial dose of quinidine.
Questioner: Did your alcoholic patient have hypokalemia?
Dr. Wasserman: No, she did not. As a matter of
fact, she came in with pelvic inflammatory disease
but unfortunately was seen by a medical intern who
was certain that he knew how to take care of her
Dosage

Plasma
Half-Life
t 1/ 2

p.o.

I.V.

Renal 10-50%
( lif jurine pH)
Liver

4- 6 hr.

2- 4 hr.

5 min.

Renal 60 %
(lif j urine pH)

3- 4 hr.

l hr.

Stat

Liver

2 hr.

Li ver

± 3 hr.

few hrs.

10 min.

.04 X l;
.Ol-.03q
6 hr. ?

0. I / min. to Heart failure; Bronchospasm;
10
Hypoglycemic Unresponsiveness;
Rash; G-l Sx

Liver

18- 24 hr.
average

1- 2 hr.

5 min.

1.0 first day
0.5 next day
then 0.4/ day

50- lOOmg
5/ min. to
1,000

Renal

±10 hr.

hrs.

15 min.

.3- . 6q
8-12 hr.

4-5 mg / Kg Initial Tachycardia;
Postural Hypotension;
Parotid pain;
Vomiting I.V.

Biotransformation

Peak Effect Time
p.o.
(gm)

I.V.

(mg)

Adverse Effects
(See Heart Effects)

0 . 4 X 1;
0.2- 0.4q
6 hr.

25 / min . to
1000

"Syncope"; Shoq:k; Hemolysis;
Thrombocytopenia; G-l Sx;
Paralys is; Cinchonism

1.0 X 1;

50 / min. to
1-2,000

Lupus; Shock; ? Syncop~;
Agranulocytosis; G-l Sx;
Psychosis; Paralysis

50-100 Stat
1-4 / min.

Twitching, Seizures;
CNS Depression; Shock

0 . Sq 3 hr.
Stat

Ataxia ; Sedation; Gums ;
Lymphoma: Lupus ; Rash;
Folate Def; Hepatitis;
Osteomalacia; Thyroiditis
Nystagmus
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Addendum 2

DIPHENYLHYDANTOIN DRUG INTERACTIONS
I.

DRUGS LEADING TO INCREASED DPH EFFECT AND TOXICITY
MECHANISM

DRUGS

A. Bishydroxycoumarin (Dicumarol ®>
B. Disulfiram (Antabuse ®)
C. Isoniazid
slow-inactivators
D . PAS

Inhibition of liver metabolism
Inhibition of liver metabolism
Not definite- probably inhibition of liver
metabolism
Unknown- Possibly due to its increased
blood levels of concommitant INH
Binding displacement of DPH
Inhibition of liver metabolism
Unknown

E. Phenylbutazone (Butazolidin ®>
F. Phenyramidol (Analexin ®)
G. Sulfaphenazole (Sulfabid ®)
and Sulthiame (Ospolot ®)
H. Salicylates
I. Chloramphenicol
J. Benzodiazepines
K. Methylphenidate (Ritalin®>

II.

Binding displacement of DPH
Inhibition of liver metabolism
Unknown
Not definite- probably inhibition of liver
metabolism

DRUGS LEADING TO DECREASED DPH EFFECT AND TOXICITY

Increased hepatic microsomal metabolism
Decreased absorption of DPH
Increased liver metabolism of DPH

A. Phenobarbital
B. Amphetamines
C. Alcohol

III.

DPH'S EFFECT ON OTHER DRUGS
DRUGS

A. Coumarin Anticoagulants
B. Corticosteroids
C. Methotrexate
D . VitaminD

EFFECT

MEC HANISM

Enhancement
Inhibition
Enhancement
Inhibition

Not definite- probably binding displacement
Increased microsomal metabolism
Binding displacement
Increased liver metabolism of Vit. D

VPC's. Of course when she developed the first
episode of ventricular fibrillation, he concluded that
he simply had not given her enough. She received
two doses of quinidine, but that was all.
Dr. Dreifus: I too use quinidine. I just want to
mention two things. The first point Dr. Surawicz
already inferred was low potassium, and this seems
to be one of the settings in which I have seen this
repetitive ventricular tachycardia with quinidine
and with other antiarrhythmic drugs that prolong
Q-T intervals. The second point, which is much more
serious, is acute coronary insufficiency with very
long Q-T intervals. It is usually seen on the basis
of sinus bradycardia. These patients do worse with
quinidine or procainamide because you may move
the premature systole into the long Q-T interval.
The VPC will bisect the T wave, and then ventricular fibrillation or runs of ventricular tachycardia
occur. Actually, the only way to deal with such
patients is to pace them. The reason I wanted to
mention this is, if patients at high risk were on a
prophylactic agent and quinidine or a congener
of quinidine was one on these agents, the patients

who were tending to develop long Q-T intervals with
their bouts of coronary insufficiency might be more
vulnerable to sudden death. This is a very serious
problem, and I think when you use quinidine you
have to take all these facts into consideration if
you want to avoid mistakes.
Dr. Dreifus: I would like to ask Dr. Wasserman if
he feels that bretylium has any membrane effects
as an antiarrhythmic agent.
Dr. Wasserman: Yes. The problem of course has
been to forget the initial articles, all of which were
merely reflecting the release norepinephrine. I
think it is quite clear that it does have direct myocardial effects. It certainly does so in the absence
of norepinephrine depleted by pretreatment reserpine or guanethidine, and it has effects which
differ from guanethidine in terms of the ventricular
fibrillation threshold which suggests that it is not
simply the depletion of catecholamines. Thus, I
think it clearly must have some effect. I think
its role is not yet clear, and I think we need to
know more about it before we can use it wisely.

